Part 4/14:
The process involves vaccinating animals to observe protective effects and testing human immune responses to ensure safety before proceeding further. Amid setbacks like lab shutdowns for safety audits, the dedicated teams adjusted schedules to meet strict deadlines, aiming for vaccine readiness by November 2020—a daunting but crucial objective amidst a global crisis. The team also navigates uncharted territories, such as deploying mRNA vaccine technology, a first for some laboratories, which offers promising insights into immune responses and potential for rapid deployment.